Loading...

Biogen Inc.

IDP.DEXETRA
Healthcare
Drug Manufacturers - General
151.64
-1.74(-1.13%)
German Market opens in 9h 26m

Biogen Inc. (IDP.DE) Stock Competitors & Peer Comparison

See (IDP.DE) competitors and their performances in Stock Market.

Peer Comparison Table: Drug Manufacturers - General Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
IDP.DE€153.06+3.38%22.5B20.40€7.52N/A
LLY.DE€787.20-1.11%749.1B40.31€19.67+0.68%
JNJ.DE€203.70+1.02%491.6B21.58€9.46+2.18%
4AB.DE€178.25+2.35%312.5B87.45€2.02+3.24%
6MK.DE€101.86-0.22%251.9B16.33€6.24+2.79%
ZEG.DE€160.70+0.59%249.2B28.75€5.59+1.69%
AMG.DE€299.65+0.94%160.1B24.31€12.22+2.78%
GIS.DE€119.42+1.84%147.8B20.53€5.80+2.30%
PFE.DE€23.03+0.46%131.5B19.93€1.16+6.35%
PFE.F€23.03+0.20%131.5B19.93€1.16+6.36%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

IDP.DE vs LLY.DE Comparison April 2026

IDP.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDP.DE stands at 22.5B. In comparison, LLY.DE has a market cap of 749.1B. Regarding current trading prices, IDP.DE is priced at €153.06, while LLY.DE trades at €787.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDP.DE currently has a P/E ratio of 20.40, whereas LLY.DE's P/E ratio is 40.31. In terms of profitability, IDP.DE's ROE is +0.07%, compared to LLY.DE's ROE of +0.98%. Regarding short-term risk, IDP.DE is less volatile compared to LLY.DE. This indicates potentially lower risk in terms of short-term price fluctuations for IDP.DE.Check LLY.DE's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions